EA
ICPT

Emerald Advisers’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Emerald Advisers’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-127,927
Closed -$8.49M – 353
2019
Q3 		$8.49M Sell
127,927
-19,482
-13% -$1.31M 0.4% 95
2019
Q2 		$11.7M Buy
147,409
+26,589
+22% +$2.38M 0.47% 82
2019
Q1 		$13.5M Buy
+120,820
New +$13.2M 0.55% 73
2018
Q1 		– Sell
-162,560
Closed -$9.5M – 269
2017
Q4 		$9.5M Buy
+162,560
New +$10.3M 0.37% 105
2017
Q1 		– Sell
-85,603
Closed -$9.3M – 271
2016
Q4 		$9.3M Buy
85,603
+9,524
+13% +$1.13M 0.4% 95
2016
Q3 		$12.5M Buy
76,079
+23,129
+44% +$3.65M 0.56% 70
2016
Q2 		$7.55M Buy
52,950
+8,811
+20% +$1.28M 0.36% 99
2016
Q1 		$5.67M Sell
44,139
-4,603
-9% -$544K 0.28% 117
2015
Q4 		$7.28M Sell
48,742
-20,656
-30% -$3.5M 0.34% 100
2015
Q3 		$11.5M Buy
69,398
+1,894
+3% +$417K 0.6% 56
2015
Q2 		$16.3M Sell
67,504
-676
-1% -$180K 0.78% 39
2015
Q1 		$18.2M Buy
68,180
+765
+1% +$166K 0.91% 25
2014
Q4 		$10.5M Buy
67,415
+59,238
+724% +$10.9M 0.56% 60
2014
Q3 		$1.94M Sell
8,177
-16,936
-67% -$4.32M 0.11% 209
2014
Q2 		$5.94M Sell
25,113
-2,000
-7% -$527K 0.34% 102
2014
Q1 		$8.94M Sell
27,113
-119,054
-81% -$40.2M 0.5% 66
2013
Q4 		$9.98M Sell
146,167
-23,376
-14% -$1.35M 0.54% 60
2013
Q3 		$11.7M Buy
169,543
+120,368
+245% +$5.94M 0.66% 43
2013
Q2 		$2.21M Buy
+49,175
New +$1.68M 0.13% 180

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Emerald Advisers's ICPT Position: Q4 2019 in Review

Emerald Advisers sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2019, closing a stake of 127,927 shares — an estimated $8.49M sold.

Emerald Advisers first reported a position in ICPT in Q2 2013 and held it in 19 quarters. The position peaked at $18.2M in Q1 2015. 215 funds tracked by Wall St. Rank hold ICPT as of Q4 2019.

  • Emerald Advisers reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Emerald Advisers sold 127,927 Intercept Pharmaceuticals, Inc. shares in Q4 2019, an estimated $8.49M.
  • Emerald Advisers first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 19 quarters.
  • Emerald Advisers's Intercept Pharmaceuticals, Inc. position peaked at $18.2M in Q1 2015.
  • 215 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2019.

Based on Emerald Advisers's 13F filing for Q4 2019, filed 29 Jan 2020.